Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of "Buy" by Analysts

Key Points

• Aura Biosciences, Inc. has an average analyst rating of "Buy", with one hold, six buys, and one strong buy among eight ratings firms.
• The company's stock price objective is set at $22.00, reflecting positive sentiment from research analysts.
• Insider transactions included a senior vice president selling 7,722 shares at $6.70, reducing their stake by 8.19% to approximately $579,938.60.

Shares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have been given an average recommendation of "Buy" by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $22.00.

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Wednesday, August 13th. Zacks Research upgraded shares of Aura Biosciences from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th.

Insider Activity at Aura Biosciences

In other news, SVP Amy Elazzouzi sold 7,722 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $6.70, for a total transaction of $51,737.40. Following the completion of the transaction, the senior vice president owned 86,558 shares of the company's stock, valued at approximately $579,938.60. The trade was a 8.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.30% of the company's stock.

Institutional Investors Weigh In On Aura Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its position in Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $40,000 after purchasing an additional 2,104 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Aura Biosciences by 5,766.9% during the first quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $57,000 after buying an additional 9,573 shares during the last quarter. Invesco Ltd. acquired a new position in shares of Aura Biosciences during the second quarter worth $76,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Aura Biosciences by 24.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company's stock valued at $78,000 after acquiring an additional 2,434 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Aura Biosciences by 286.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company's stock valued at $85,000 after acquiring an additional 10,007 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Price Performance

Aura Biosciences stock opened at $6.02 on Friday. The firm has a market cap of $373.96 million, a PE ratio of -3.07 and a beta of 0.45. The stock's fifty day moving average price is $6.48 and its two-hundred day moving average price is $6.22. Aura Biosciences has a one year low of $4.34 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Sell-side analysts expect that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.